Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

04 mai 2018 07h00 HE | Source: Agios Pharmaceuticals, Inc.

Agios Provides Business Update on Discovery Research Strategy and Pipeline, Progress on Clinical Programs, Commercial Launch Preparations and Reports First Quarter 2018 Financial Results at Investor Day

– Commercial Infrastructure In Place Ahead of August 21, 2018 PDUFA Action Date for TIBSOVO® (Ivosidenib) for IDH1m R/R AML – – Clinical Portfolio Advancing with Four Compounds in Development and...
27 avr. 2018 07h00 HE | Source: Agios Pharmaceuticals, Inc.

Agios Announces Revised Starting Time of 8:00am ET for Investor Day and First Quarter 2018 Financial Results Webcast on Friday, May 4, 2018

CAMBRIDGE, Mass., April 27, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today...
11 avr. 2018 07h00 HE | Source: Agios Pharmaceuticals, Inc.

Agios to Webcast Investor Day and First Quarter 2018 Financial Results on Friday, May 4, 2018

CAMBRIDGE, Mass., April 11, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today...
19 mars 2018 07h01 HE | Source: Agios Pharmaceuticals, Inc.

Agios Announces First Patient Dosed with MAT2A Inhibitor AG-270 in Phase 1 Study in Patients with Advanced Solid Tumors or Lymphoma with an MTAP Deletion

CAMBRIDGE, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today...
05 mars 2018 07h01 HE | Source: Agios Pharmaceuticals, Inc.

Agios to Present at the Cowen 38th Annual Healthcare Conference Monday, March 12, 2018

CAMBRIDGE, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today...
15 févr. 2018 11h58 HE | Source: Agios Pharmaceuticals, Inc.

FDA Accepts New Drug Application and Grants Priority Review for Ivosidenib in Relapsed or Refractory AML with an IDH1 Mutation

– PDUFA date set for August 21, 2018 – CAMBRIDGE, Mass., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer...
14 févr. 2018 07h01 HE | Source: Agios Pharmaceuticals, Inc.

Agios Reports Fourth Quarter and Full Year 2017 Financial Results

– All 2017 Key Milestones Achieved, Including First U.S. Product Approval from Agios’ Discovery Platform and NDA Submission for Second Product Candidate, Ivosidenib, for IDH1m R/R AML – – 2018...
31 janv. 2018 16h01 HE | Source: Agios Pharmaceuticals, Inc.

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2017 Financial Results on February 14, 2018

CAMBRIDGE, Mass., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced...
23 janv. 2018 16h01 HE | Source: Agios Pharmaceuticals, Inc.

Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

CAMBRIDGE, Mass., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced the closing of its previously announced underwritten public offering of common stock,...
18 janv. 2018 20h43 HE | Source: Agios Pharmaceuticals, Inc.

Agios Announces Pricing of $475 Million Public Offering of Common Stock

CAMBRIDGE, Mass., Jan. 18, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that it has priced an underwritten public offering of 7,089,553 shares of common stock...

Page précédente